<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="scad" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">scad</book-part-id>
      <title-group>
        <title>Short-Chain Acyl-CoA Dehydrogenase Deficiency</title>
        <alt-title alt-title-type="alt-title">Synonym: SCAD Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wolfe</surname>
            <given-names>Lynne</given-names>
          </name>
          <degrees>MS, CRNP, BC</degrees>
          <aff>NIH/NHGRI<break/>Bethesda, Maryland</aff>
          <email>lynne.wolfe@nih.gov</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jethva</surname>
            <given-names>Reena</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>St Christopher&#x02019;s Hospital for Children<break/>Philadelphia, Pennsylvania</aff>
          <email>reena.jethva@drexelmed.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Oglesbee</surname>
            <given-names>Devin</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Mayo Clinic<break/>Rochester, Minnesota</aff>
          <email>oglesbee.devin@mayo.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vockley</surname>
            <given-names>Jerry</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>University of Pittsburgh<break/>Pittsburgh, Pennsylvania</aff>
          <email>gerard.vockley@chp.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>22</day>
          <month>9</month>
          <year>2011</year>
        </date>
        <date date-type="updated">
          <day>7</day>
          <month>8</month>
          <year>2014</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="short" document-type="chapter">SHORT Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="sgs" document-type="chapter">Shprintzen-Goldberg Syndrome</related-object>
      <abstract id="scad.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>The clinical findings in those with confirmed short-chain acyl-CoA dehydrogenase (SCAD) deficiency range from severe (dysmorphic facial features, feeding difficulties/failure to thrive, metabolic acidosis, ketotic hypoglycemia, lethargy, developmental delay, seizures, hypotonia, dystonia, and myopathy) to normal. As in other fatty acid oxidation disorders, characteristic biochemical findings of SCAD deficiency may be absent except during times of physiologic stress such as fasting and illness. In the largest series of affected individuals published to date, 20% had failure to thrive, feeding difficulties, and hypotonia; 22% had seizures, and 30% had hypotonia without seizures. In contrast, the majority of infants with SCAD deficiency have been detected by expanded newborn screening, and the great majority of these infants remain asymptomatic. Because most infants with SCAD deficiency identified through newborn screening programs have been well at the time of diagnosis and asymptomatic relatives who meet diagnostic criteria are reported, the relationship of clinical manifestations to SCAD deficiency has come into question.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>SCAD deficiency has been defined as the presence of:</p>
          <list list-type="bullet">
            <list-item>
              <p>Increased butyrylcarnitine (C4) concentrations in plasma and/or increased ethylmalonic acid (EMA) concentrations in urine under non-stressed conditions (on at least two occasions)</p>
              <p>AND</p>
            </list-item>
            <list-item>
              <p>Biallelic <italic toggle="yes">ACADS</italic> pathogenic variants or one pathogenic variant in <italic toggle="yes">trans</italic> with an <italic toggle="yes">ACADS</italic> susceptibility variant.</p>
            </list-item>
          </list>
          <p>Of note, it is recommended that other diagnoses be pursued as appropriate in symptomatic individuals (especially infants and young children) with a presumptive diagnosis of SCAD deficiency.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> As most individuals with SCAD deficiency are asymptomatic, the need for treatment when well is unclear. There are no generally accepted recommendations for dietary manipulation or use of carnitine and/or riboflavin supplementation.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> An age-appropriate heart-healthy diet; avoidance of fasting longer than age-appropriate fasting periods for infants and toddlers and longer than 12 hours for older children.</p>
          <p><italic toggle="yes">Surveillance:</italic> Annual visits to a metabolic clinic to assess growth and development and nutritional status (including protein and iron stores, levels of RBC or plasma essential fatty acids and plasma carnitine). Closer follow up and surveillance as needed for those with a history of metabolic acidosis, hypoglycemia, and/or other acutely presenting symptoms.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>SCAD deficiency is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if the pathogenic and/or susceptibility variants in the family have been identified. Of note, requests for prenatal testing for conditions which (like SCAD deficiency) may not affect intellect and have a high likelihood of normal clinical outcome are not common.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="scad.Diagnosis">
        <title>Diagnosis</title>
        <sec id="scad.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>In the US, most infants with short-chain acyl CoA dehydrogenase (SCAD) deficiency are identified through newborn screening (NBS) programs.</p>
          <p>Older children and adults may be identified with SCAD deficiency after undergoing a biochemical evaluation, typically for hypotonia, dystonia, seizures, metabolic acidosis associated with illness, and/or hypoglycemia [<xref ref-type="bibr" rid="scad.REF.corydon.2001.18">Corydon et al 2001</xref>].</p>
        </sec>
        <sec id="scad.Testing">
          <title>Testing</title>
          <p>SCAD deficiency has been defined by <xref ref-type="bibr" rid="scad.REF.van_maldegem.2006.943">van Maldegem et al [2006]</xref> as the presence of:</p>
          <list list-type="bullet">
            <list-item>
              <p>On at least two occasions, increased butyrylcarnitine (C4) concentrations in plasma or bloodspot, and/or increased ethylmalonic acid (EMA) concentrations in urine under non-stressed conditions;</p>
            </list-item>
            <list-item>
              <p>Biallelic <italic toggle="yes">ACADS</italic> pathogenic variants or compound heterozygosity for pathogenic variants and a susceptibility variant (see <xref ref-type="sec" rid="scad.Molecular_Genetics">Molecular Genetics</xref>). Pathogenic variants are typically missense changes that inactivate or impair SCAD enzymatic activity; the known susceptibility variants are <xref ref-type="table" rid="scad.T.selected_acads_variants">c.511C&#x0003e;T</xref> and <xref ref-type="table" rid="scad.T.selected_acads_variants">c.625G&#x0003e;A</xref> (see <xref ref-type="sec" rid="scad.Molecular_Genetics">Molecular Genetics</xref>). The susceptibility variants are thought to represent a susceptibility state that requires one or more other genetic (e.g., a pathogenic <italic toggle="yes">ACADS</italic> variant in <italic toggle="yes">trans</italic>) or environmental factors to be present for disease to development [<xref ref-type="bibr" rid="scad.REF.gregersen.2001.169">Gregersen et al 2001</xref>, <xref ref-type="bibr" rid="scad.REF.van_maldegem.2010c.507">van Maldegem et al 2010c</xref>].</p>
              <p>In the literature, the genotypes of individuals with SCAD deficiency may be generally described as mutation/mutation, mutation/variant, or variant/variant.</p>
            </list-item>
          </list>
          <p>Relatives are considered affected if they have the same <italic toggle="yes">ACADS</italic> genotype as the proband and increased C4-C concentrations in plasma and/or increased EMA concentrations in urine [<xref ref-type="bibr" rid="scad.REF.van_maldegem.2006.943">van Maldegem et al 2006</xref>].</p>
          <p>
            <bold>Acylcarnitine profile</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Acylcarnitine analysis by tandem mass spectrometry is used to detect elevated blood C4 (butyrylcarnitine) on newborn screening.</p>
              <p>Note: (1) Normal ranges for isolated C4 vary from state to state, necessitating confirmatory testing consistent with the American College of Medical Genetics (ACMG) ACT Sheets (see <named-content content-type="highlight-1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.acmg.net/StaticContent/ACT/C4.pdf">ACMG-ACT Sheet</ext-link></named-content>). Depending on the screening cutoff values used for butyrylcarnitine concentration, most infants with abnormal results are either homozygous for a pathogenic variant on both <italic toggle="yes">ACADS</italic> alleles or compound heterozygous for a pathogenic variant on one allele and a common susceptibility variant (<xref ref-type="table" rid="scad.T.selected_acads_variants">c.511C&#x0003e;T</xref> or <xref ref-type="table" rid="scad.T.selected_acads_variants">c.625G&#x0003e;A</xref>) on the other allele [<xref ref-type="bibr" rid="scad.REF.lindner.2010.521">Lindner et al 2010</xref>]; however, butyrylcarnitine concentrations from newborns homozygous for the <xref ref-type="table" rid="scad.T.selected_acads_variants">c.625G&#x0003e;A</xref> variant overlap with butyrylcarnitine concentrations in newborns homozygous for a pathogenic variant or compound heterozygous for a pathogenic variant and a susceptibility variant. Thus, molecular confirmation of the diagnosis of SCAD deficiency is still often necessary. (2) Isobutyryl-CoA dehydrogenase deficiency (IBDD) that leads to elevation of isobutyrylcarnitine, a C4 species also detectable by NBS, must be distinguished from SCAD deficiency by additional laboratory testing.</p>
            </list-item>
            <list-item>
              <p>Plasma acylcarnitines can also be used when age-referenced norms are available to detect C4 elevations in older children and adults suspected of having SCAD deficiency.</p>
            </list-item>
          </list>
          <p><bold>Urine acylglycines.</bold> A random urine sample can be used to differentiate butyrylglycine and isobutyrylglycine and to detect elevated EMA as part of either confirmatory testing after a positive newborn screen or diagnostic testing in older children and adults being evaluated for SCAD deficiency.</p>
          <p><bold>Urine organic acids.</bold> A random urine sample can be collected to detect EMA and dicarboxylic acids, which may be helpful in confirmation of an abnormal newborn screen or during acute illnesses. Urine organic acid screening in symptomatic older children and adults may reveal elevated EMA [<xref ref-type="bibr" rid="scad.REF.pedersen.2008.43">Pedersen et al 2008</xref>]. While butyrylcarnitine concentrations from newborns homozygous for the <xref ref-type="table" rid="scad.T.selected_acads_variants">c.625G&#x0003e;A</xref> variant overlap with butyrylcarnitine concentrations in newborns with biallelic pathogenic variants or with compound heterozygosity for a pathogenic variant and a susceptibility variant, other biochemical data from urine organic acids (e.g., ethylmalonic acid and methylsuccinic acid levels) tend to be significantly higher in patients with two deleterious pathogenic variants [<xref ref-type="bibr" rid="scad.REF.gallant.2012.55">Gallant et al 2012</xref>].</p>
          <p><bold>Carnitine levels.</bold> Total and free carnitine levels can be used to detect free carnitine deficiency; however, carnitine levels are usually normal in individuals with SCAD deficiency.</p>
          <p><bold>SCAD enzyme activity</bold> is difficult to obtain clinically and probably not helpful.</p>
          <p><bold>Skin fibroblast, fatty acid oxidation studies.</bold> In vitro fatty acid probe analysis, a functional assay that assesses function of the entire beta-oxidation pathway, can reflect residual enzyme levels, which may be useful clinically to confirm SCAD deficiency [<xref ref-type="bibr" rid="scad.REF.young.2003.103">Young et al 2003</xref>].</p>
          <sec id="scad.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">ACADS</italic> is the only gene in which pathogenic variants are known to cause short-chain acyl-CoA dehydrogenase (SCAD) deficiency.</p>
            <table-wrap id="scad.T.summary_of_molecular_genetic_test" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in SCAD Deficiency</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_scad.T.summary_of_molecular_genetic_test_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_scad.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_scad.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_scad.T.summary_of_molecular_genetic_test_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">ACADS</italic>
                    </td>
                    <td headers="hd_h_scad.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_scad.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">~100%&#x000a0;<sup>3</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_scad.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Targeted analysis for pathogenic variants&#x000a0;<sup>4,&#x000a0;5</sup></td>
                    <td headers="hd_h_scad.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">61% for these 3 nucleotide changes&#x000a0;<sup>5</sup>, but may be higher in certain populations</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_scad.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis of select exons&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_scad.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">See footnote 7</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_scad.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>8</sup></td>
                    <td headers="hd_h_scad.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown, None reported</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="scad.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="scad" object-id="scad.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="scad.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="scad.TF.1.2">
                  <label>2. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of unknown significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="scad.TF.1.3">
                  <label>3. </label>
                  <p>In individuals with biochemical findings consistent with the diagnosis of SCAD deficiency</p>
                </fn>
                <fn id="scad.TF.1.4">
                  <label>4. </label>
                  <p>Testing for a specific pathogenic variant(s) or susceptibilty variants. Note: Variants included in a panel may vary by laboratory.</p>
                </fn>
                <fn id="scad.TF.1.5">
                  <label>5. </label>
                  <p>Pathogenic variants tested for may include <xref ref-type="table" rid="scad.T.selected_acads_variants">c.319C&#x0003e;T</xref> and the susceptibility variants <xref ref-type="table" rid="scad.T.selected_acads_variants">c.511C&#x0003e;T</xref>, <xref ref-type="table" rid="scad.T.selected_acads_variants">c.625G&#x0003e;A</xref>.</p>
                </fn>
                <fn id="scad.TF.1.6">
                  <label>6. </label>
                  <p>Susceptibility variants <xref ref-type="table" rid="scad.T.selected_acads_variants">c.511C&#x0003e;T</xref> and <xref ref-type="table" rid="scad.T.selected_acads_variants">c.625G&#x0003e;A</xref> in exons 5 and 6 are typically included in targeted analysis.</p>
                </fn>
                <fn id="scad.TF.1.7">
                  <label>7. </label>
                  <p>May be useful for follow up of abnormal newborn screening and/or elevated ethylmalonic acid results.</p>
                </fn>
                <fn id="scad.TF.1.8">
                  <label>8. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="scad.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm the diagnosis in a proband.</bold> See <named-content content-type="highlight-1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.acmg.net/StaticContent/ACT/C4.pdf">ACMG-ACT Sheet</ext-link></named-content>.</p>
          <list list-type="order">
            <list-item>
              <label>1</label>
              <p>Obtain acylcarnitine profile from a dried blood spot (newborn screening) or plasma. If C4-C (butyrylcarnitine) is elevated:</p>
            </list-item>
            <list-item>
              <label>2</label>
              <p>Analyze urine acylglycines or urine organic acids to confirm that C4 (butyrylcarnitine) is elevated and/or ethylmalonic acid (EMA) concentrations are increased; then:</p>
            </list-item>
            <list-item>
              <label>3</label>
              <p>Perform molecular genetic testing to confirm the diagnosis of SCAD deficiency using ONE of the following:</p>
            </list-item>
          </list>
          <list list-type="bullet">
            <list-item>
              <p>Sequence analysis of <italic toggle="yes">ACADS</italic></p>
            </list-item>
            <list-item>
              <p>For some individuals:</p>
              <list list-type="bullet">
                <list-item>
                  <p>A targeted pathogenic variant panel comprising the <italic toggle="yes">ACADS</italic> pathogenic variant <xref ref-type="table" rid="scad.T.selected_acads_variants">c.319C&#x0003e;T</xref> and the susceptibility variants <xref ref-type="table" rid="scad.T.selected_acads_variants">c.511C&#x0003e;T</xref> and <xref ref-type="table" rid="scad.T.selected_acads_variants">c.625G&#x0003e;A</xref>.</p>
                </list-item>
                <list-item>
                  <p>If neither or only one variant is identified, sequence analysis of <italic toggle="yes">ACADS</italic></p>
                </list-item>
              </list>
            </list-item>
          </list>
          <list list-type="order">
            <list-item>
              <label>4</label>
              <p>If no <italic toggle="yes">ACADS</italic> pathogenic variant is identified consider <italic toggle="yes">ETHE1</italic> sequence analysis to detect EMA encephalopathy [<xref ref-type="bibr" rid="scad.REF.tiranti.2004.239">Tiranti et al 2004</xref>]. See <xref ref-type="sec" rid="scad.Differential_Diagnosis">Differential Diagnosis</xref>.</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="scad.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="scad.Clinical_Description">
          <title>Clinical Description</title>
          <p>The phenotypic spectrum described in short-chain acyl-CoA dehydrogenase (SCAD) deficiency ranges from severe (dysmorphic facial features, feeding difficulties/failure to thrive, metabolic acidosis, ketotic hypoglycemia, lethargy, developmental delay, seizures, hypotonia, dystonia, and myopathy) to normal, raising questions about the relationship between the biochemical phenotype and clinical manifestations [<xref ref-type="bibr" rid="scad.REF.gregersen.2001.169">Gregersen et al 2001</xref>, <xref ref-type="bibr" rid="scad.REF.van_maldegem.2006.943">van Maldegem et al 2006</xref>, <xref ref-type="bibr" rid="scad.REF.jethva.2008.195">Jethva et al 2008</xref>, <xref ref-type="bibr" rid="scad.REF.pedersen.2008.43">Pedersen et al 2008</xref>, <xref ref-type="bibr" rid="scad.REF.van_maldegem.2010c.507">van Maldegem et al 2010c</xref>].</p>
          <p>SCAD deficiency was first reported in two neonates who had increased urinary ethylmalonic acid (EMA) excretion; the diagnosis was confirmed enzymatically in skin fibroblasts [<xref ref-type="bibr" rid="scad.REF.amendt.1987.1303">Amendt et al 1987</xref>]. One of these infants died of overwhelming neonatal acidosis as would be typical of an organic acidemia. However, over the last 20 years more experience with the natural history of SCAD deficiency in persons with the biochemical phenotype has identified a much broader phenotypic spectrum than originally anticipated.</p>
          <p>In the largest series published to date, <xref ref-type="bibr" rid="scad.REF.pedersen.2008.43">Pedersen et al [2008]</xref> summarized the findings in 114 affected individuals who were mostly children undergoing metabolic evaluation for developmental delay. Among the 114 with developmental delay, three sub-groups were identified:</p>
          <list list-type="bullet">
            <list-item>
              <p>23 (20%) with failure to thrive, feeding difficulties, and hypotonia</p>
            </list-item>
            <list-item>
              <p>25 (22%) with seizures</p>
            </list-item>
            <list-item>
              <p>34 (30%) with hypotonia without seizures</p>
            </list-item>
          </list>
          <p>Four individuals were asymptomatic, identified either through family studies or newborn screening programs.</p>
          <p>In a retrospective study from the Netherlands, <xref ref-type="bibr" rid="scad.REF.van_maldegem.2006.943">van Maldegem et al [2006]</xref> identified 31 individuals who met the biochemical and molecular diagnostic criteria for SCAD deficiency who also had sufficient information on health and development. The most frequently reported clinical findings were developmental delay (16; designated as &#x0201c;non-severe&#x0201d; in 15), epilepsy (11; non-severe in all), behavioral disorder (8; non-severe in 5), and history of hypoglycemia (6; non-severe in 5). Follow up ranged from one to 18 years: two had progressive clinical deterioration, 12 had no change in clinical findings, eight improved, and nine had complete recovery. In addition, three parents and six sibs were found to have <italic toggle="yes">ACADS</italic> genotypes that were identical to the proband; eight of the nine had increased levels of C4-C and/or EMA and one of the six sibs had transient feeding difficulties in the first year.</p>
          <p>In a study of ten affected individuals of Ashkenazi Jewish ancestry, eight had developmental delay and four had muscle biopsy-proven mini-multicore myopathy [<xref ref-type="bibr" rid="scad.REF.tein.2008.179">Tein et al 2008</xref>]. It has been noted that persons with SCAD deficiency with a myopathy reported as multiminicore disease had not undergone a full evaluation and may have had another unrelated cause for their muscle disease such as mutation of <italic toggle="yes">RYR1</italic> or <italic toggle="yes">SELENON (SEPN1)</italic> [<xref ref-type="bibr" rid="scad.REF.van_maldegem.2010c.507">van Maldegem et al 2010c</xref>]. (See <related-object link-type="booklink" source-id="gene" document-id="mmd" document-type="chapter">Multiminicore Disease</related-object>.)</p>
          <p>As in other fatty acid oxidation disorders, characteristic biochemical findings of SCAD deficiency may be absent in affected individuals except during times of physiologic stress including fasting and illness [<xref ref-type="bibr" rid="scad.REF.bok.2003.1152">Bok et al 2003</xref>, <xref ref-type="bibr" rid="scad.REF.pedersen.2008.43">Pedersen et al 2008</xref>]. In addition, manifestations early in life that could be attributed to SCAD deficiency appear to resolve completely during long-term follow up for most individuals diagnosed with SCAD.</p>
          <p>Since most infants with SCAD deficiency identified through newborn screening programs have been well at the time of diagnosis, the reported relationship of clinical manifestations to the deficiency of SCAD has come into question [<xref ref-type="bibr" rid="scad.REF.waisbren.2008.39">Waisbren et al 2008</xref>]. If there is an increased risk for clinical manifestations, it is most likely in those individuals with biallelic pathogenic variants that inactivate or impair enzymatic activity. Individuals with biallelic susceptibility variants (<xref ref-type="table" rid="scad.T.selected_acads_variants">c.511C&#x0003e;T</xref> and <xref ref-type="table" rid="scad.T.selected_acads_variants">c.625G&#x0003e;A</xref>) are so frequent in the general population that this finding cannot represent a significant risk for clinical disease (see <xref ref-type="sec" rid="scad.Molecular_Genetics">Molecular Genetics</xref>). Individuals with an inactivating pathogenic variant on one allele and a susceptibility variant on the other have enzymatic dysfunction that falls between the other two groups, as may their clinical risk. The largest series to date of diagnosed cases was from California newborn screening data and indicated that even when associated with two pathogenic variants, babies with SCAD deficiency remained asymptomatic [<xref ref-type="bibr" rid="scad.REF.gallant.2012.55">Gallant et al 2012</xref>].</p>
          <p>Since the long-term risk for development of symptoms is not known, it seems prudent to:</p>
          <list list-type="bullet">
            <list-item>
              <p>Offer individuals diagnosed with SCAD deficiency ongoing follow up in order to monitor them and expand clinical knowledge of the disorder;</p>
            </list-item>
            <list-item>
              <p>Consider post-mortem evaluation and testing to determine cause of death in any individual with a diagnosis of SCAD deficiency since the disorder is not usually life threatening;</p>
            </list-item>
            <list-item>
              <p>Proceed with further diagnostic evaluation in symptomatic individuals (especially infants and young children) with a presumptive diagnosis of SCAD deficiency [<xref ref-type="bibr" rid="scad.REF.pedersen.2008.43">Pedersen et al 2008</xref>, <xref ref-type="bibr" rid="scad.REF.bennett.2010.533">Bennett 2010</xref>, <xref ref-type="bibr" rid="scad.REF.van_maldegem.2010c.507">van Maldegem et al 2010c</xref>].</p>
            </list-item>
          </list>
          <p><bold>Pregnancy-related issues.</bold> Acute fatty liver of pregnancy (AFLP), preeclampsia, and/or HELLP syndrome in mothers of affected fetuses have been described [<xref ref-type="bibr" rid="scad.REF.matern.2001.585">Matern et al 2001</xref>, <xref ref-type="bibr" rid="scad.REF.bok.2003.1152">Bok et al 2003</xref>, <xref ref-type="bibr" rid="scad.REF.van_maldegem.2010c.507">van Maldegem et al 2010c</xref>].</p>
        </sec>
        <sec id="scad.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No consistent clinical phenotype-genotype correlations have been observed. However, recent data have suggested a correlation between urinary levels of biomarkers (ethylmalonic acid and methylsuccinic acid) and presence of biallelic pathogenic variants or one pathogenic and one susceptibility variant on each allele [<xref ref-type="bibr" rid="scad.REF.gallant.2012.55">Gallant et al 2012</xref>].</p>
        </sec>
        <sec id="scad.Prevalence">
          <title>Prevalence</title>
          <p>Using fairly strict biochemical and molecular criteria, a birth prevalence of at least 1:50,000 has been estimated in the Netherlands [<xref ref-type="bibr" rid="scad.REF.van_maldegem.2006.943">van Maldegem et al 2006</xref>]. A prevalence of 1:34,632 or approximately 1:35,000 was calculated from California data for the incidence in the USA [<xref ref-type="bibr" rid="scad.REF.gallant.2012.55">Gallant et al 2012</xref>].</p>
          <p>SCAD deficiency appears to be pan ethnic.</p>
        </sec>
      </sec>
      <sec id="scad.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with mutation of <italic toggle="yes">ACADS.</italic></p>
      </sec>
      <sec id="scad.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Isobutryl acyl-CoA dehydrogenase deficiency and SCAD deficiency must be differentiated by confirmatory testing of C4-C elevations identified on newborn screen.</p>
        <p>Other disorders to consider in the differential diagnosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Glutaric acidemia type II (GAII), also known as multiple acyl-CoA dehydrogenase deficiency (MADD) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/231680">231680</ext-link>)</p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="ee" document-type="chapter">Ethylmalonic encephalopathy</related-object>
            </p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="mt-overview" document-type="chapter">Mitochondrial respiratory chain defects</related-object>
            </p>
          </list-item>
          <list-item>
            <p>Jamaican vomiting sickness</p>
          </list-item>
        </list>
      </sec>
      <sec id="scad.Management">
        <title>Management</title>
        <sec id="scad.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs of an individual diagnosed with short-chain acyl-CoA dehydrogenase (SCAD) deficiency, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Carnitine levels. Total and free carnitine levels can be used to detect free carnitine deficiency; however, carnitine levels are usually normal in individuals with SCAD deficiency.</p>
            </list-item>
            <list-item>
              <p>Urine organic acids; used to detect ethylmalonic acid (EMA) during acute illnesses</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="scad.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Since most individuals with SCAD deficiency are asymptomatic, the need for treatment when well is unclear.</p>
          <p>Given the paucity of research, especially long-term follow up studies, there are no generally accepted recommendations for dietary manipulation or the use of carnitine and/or riboflavin supplementation in SCAD deficiency.</p>
          <p>However, since the risk for episodes of metabolic decompensation is increased above background risk, increased alertness for dehydration, metabolic acidosis, and/or hypoglycemia during times of otherwise minor illness is prudent.</p>
          <p>Basic management of acute metabolic acidosis should be similar to that for other fatty acid oxidation disorders: promoting anabolism and providing alternative sources of energy, both of which can be accomplished by administration of intravenous fluids with high dextrose concentrations with or without insulin. Usually 10% dextrose is given at a rate to provide 8-10 mg/kg/min of glucose. This approach is especially important if nausea and vomiting prevent the oral intake of fluids.</p>
          <p>Hypoglycemia is uncommon but can be treated in the same fashion as acute metabolic acidosis.</p>
          <p>Flavin adenine dinucleotide (FAD) is an essential cofactor for SCAD function. Thus, riboflavin (vitamin B<sub>2</sub>) supplementation has been suggested as a possible therapy for SCAD deficiency. In one study, a Dutch cohort of 16 individuals with confirmed SCAD deficiency and at-risk genotypes (biallelic for pathogenic variants; compound heterozygous for pathogenic variant and a susceptibility variant; biallelic for susceptibility variants) were treated with riboflavin 10 mg/kg/day for a maximum dose of 150 mg divided three times daily [<xref ref-type="bibr" rid="scad.REF.van_maldegem.2010b.304">van Maldegem et al 2010b</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>FAD levels were within normal range in all individuals throughout the study, though they were the lowest in the subgroups with genotypes that were either compound heterozygous for pathogenic variant and susceptibility variant or biallelic for a susceptibility variant.</p>
            </list-item>
            <list-item>
              <p>Plasma levels of C4-C (butrylcarnitine) remained essentially unchanged throughout the study period across all subgroups.</p>
            </list-item>
            <list-item>
              <p>Urine EMA levels decreased only in the subgroup of compound heterozygotes for pathogenic variant and susceptibility variant.</p>
            </list-item>
            <list-item>
              <p>Four of 16 demonstrated biochemical changes and exhibited clinical improvement per parent report. Of note, these four individuals had the lowest baseline FAD levels and maintained biochemical and clinical improvements even after riboflavin supplements were discontinued. No genotype-phenotype correlations for riboflavin responsiveness could be identified.</p>
            </list-item>
          </list>
          <p>In another retrospective study, 15 individuals with SCAD deficiency ascertained over a period of seven years were challenged with fasting and fat-loading tests [<xref ref-type="bibr" rid="scad.REF.van_maldegem.2010a.121">van Maldegem et al 2010a</xref>]. Three genotypic subgroups were defined: biallelic for pathogenic variants, heterozygous for a pathogenic variant and a susceptibility variant, and biallelic for susceptibility variants.</p>
          <list list-type="bullet">
            <list-item>
              <p>Free carnitine levels were normal in all individuals.</p>
            </list-item>
            <list-item>
              <p>When fasted, three individuals developed ketotic hypoglycemia associated with decreased insulin levels and increased levels of growth hormone and cortisol. Lactate, pyruvate, and plasma ammonia concentrations were normal and plasma amino acid concentrations were consistent with normal gluconeogenesis and normal proximal urea cycle function [<xref ref-type="bibr" rid="scad.REF.van_maldegem.2010a.121">van Maldegem et al 2010a</xref>].</p>
              <p>Note: In contrast, in disorders of medium- and long-chain fatty acid oxidation, fasting has been associated with a Reye-like illness with elevated plasma ammonia concentrations and severe hypoketotic hypoglycemia, suggesting impairment of gluconeogenesis and the proximal urea cycle.</p>
            </list-item>
            <list-item>
              <p>Fat loading elicited a normal ketogenic response without a rise in urine EMA, confirming previous speculation that ketogenesis is likely normal in SCAD deficiency [<xref ref-type="bibr" rid="scad.REF.bennett.2010.533">Bennett 2010</xref>, <xref ref-type="bibr" rid="scad.REF.van_maldegem.2010a.121">van Maldegem et al 2010a</xref>].</p>
            </list-item>
          </list>
          <p>In the two studies described above as well as previous case reports, hypoglycemia occurred in fewer than 20% of individuals with SCAD deficiency and normal ketogenesis was observed, ensuring cellular energy during some physiologic stressors.</p>
        </sec>
        <sec id="scad.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p>Preventive measures if necessary include avoidance of fasting longer than 12 hours (during childhood) and an age-appropriate heart-healthy diet. Age-appropriate shorter fasting periods would be required in infants and toddlers. No dietary fat restriction or specific supplements are recommended in SCAD deficiency [<xref ref-type="bibr" rid="scad.REF.bennett.2010.533">Bennett 2010</xref>, <xref ref-type="bibr" rid="scad.REF.van_maldegem.2010a.121">van Maldegem et al 2010a</xref>].</p>
        </sec>
        <sec id="scad.Surveillance">
          <title>Surveillance</title>
          <p>Longitudinal follow up of persons with SCAD deficiency may be helpful in order to more clearly define the natural history over the life span, including annual visits to a metabolic clinic to assess growth and development as well as nutritional status (protein and iron stores, concentration of RBC or plasma essential fatty acids, and plasma carnitine concentration).</p>
          <p>For individuals with a history of metabolic acidosis, hypoglycemia, and/or other acutely presenting symptoms, the need for closer follow up and surveillance should be determined by the physician.</p>
        </sec>
        <sec id="scad.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Fasting longer than 12 hours especially during a febrile or gastrointestinal illness may predispose an affected individual to dehydration, metabolic acidosis, and/or hypoglycemia. Shorter fasting periods (at least the normal age-appropriate recommendations) should be followed in infants and toddlers.</p>
        </sec>
        <sec id="scad.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate the older and younger sibs of a proband in order to identify as early as possible those who would benefit from institution of treatment and preventive measures.</p>
          <list list-type="bullet">
            <list-item>
              <p>If the pathogenic and/or susceptibility variants in the family are known, molecular genetic testing can be used to clarify the genetic status of at-risk sibs.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic and/or susceptibility variants in the family are not known, biochemical genetic testing, such as plasma acylcarnitines and urinary organic acids, can be used to clarify the genetic status of at-risk sibs.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="scad.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="scad.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Mothers of children diagnosed with fatty acid oxidation disorders, including SCAD deficiency, should inform their obstetrician so that routine monitoring for pregnancy complications can be observed.</p>
        </sec>
        <sec id="scad.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="scad.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="scad.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Short-chain acyl-CoA dehydrogenase (SCAD) deficiency is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="scad.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one pathogenic allele).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with SCAD deficiency are obligate heterozygotes (carriers) for an <italic toggle="yes">ACADS</italic> pathogenic or susceptibility variant.</p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="scad.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible if the pathogenic and/or susceptibility variants in the family have been identified.</p>
        </sec>
        <sec id="scad.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="scad.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="scad.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Molecular genetic testing.</bold> Once the <italic toggle="yes">ACADS</italic> pathogenic and/or susceptibility variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible.</p>
          <p><bold>Biochemical genetic testing.</bold> If both variants have not been identified, results of quantification of butyrylcarnitine or butyrylglycine in amniotic fluid may identify affected fetuses; however, the sensitivity and specificity are unknown.</p>
          <p>Requests for prenatal testing for conditions which (like SCAD deficiency) do not affect intellect and have a high likelihood of normal clinical outcome are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although decisions about prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="scad.Resources">
        <title>Resources</title>
      </sec>
      <sec id="scad.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="scad.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Possible pathogenic explanations for the observation that most individuals with short-chain acyl-CoA dehydrogenase (SCAD) deficiency do not present with the classic picture of metabolic acidosis and hypoketotic hypoglycemia characteristic of many fatty acid oxidation disorders include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>SCAD is only needed at the end of the &#x003b2;-oxidation cycle; therefore, gluconeogenesis and ketogenic capacity from the preceding steps of fatty acid oxidation may be sufficient to meet cellular energy needs [<xref ref-type="bibr" rid="scad.REF.van_maldegem.2010b.304">van Maldegem et al 2010b</xref>].</p>
            </list-item>
            <list-item>
              <p>Overlapping substrate specificity by medium-chain acyl CoA dehydrogenase (MCAD) may partially compensate for deficient SCAD activity [<xref ref-type="bibr" rid="scad.REF.bennett.2010.533">Bennett 2010</xref>].</p>
            </list-item>
            <list-item>
              <p>Developmental delay and seizures, findings uncommon in other fatty acid oxidation defects, raise the possibility of a neurotoxic effect in SCAD deficiency directly related to metabolite accumulation [<xref ref-type="bibr" rid="scad.REF.gregersen.2001.169">Gregersen et al 2001</xref>, <xref ref-type="bibr" rid="scad.REF.jethva.2008.195">Jethva et al 2008</xref>, <xref ref-type="bibr" rid="scad.REF.van_maldegem.2010c.507">van Maldegem et al 2010c</xref>].</p>
              <list list-type="bullet">
                <list-item>
                  <p>Ethylmalonic acid (EMA) inhibits creatine kinase activity, increases lipid peroxidation and protein oxidation, and reduces glutathione levels in the cerebral cortex of Wistar rats [<xref ref-type="bibr" rid="scad.REF.chen.2003.219">Chen et al 2003</xref>, <xref ref-type="bibr" rid="scad.REF.schuck.2010.298">Schuck et al 2010</xref>].</p>
                </list-item>
                <list-item>
                  <p>EMA inhibits electron transport chain activity in vitro [<xref ref-type="bibr" rid="scad.REF.barschak.2006.11">Barschak et al 2006</xref>].</p>
                </list-item>
                <list-item>
                  <p>Dicarboxylic acids such as EMA do not cross the blood-brain barrier, and thus sequester in the CNS, another possible explanation of EMA toxicity resulting in neurologic findings [<xref ref-type="bibr" rid="scad.REF.schuck.2010.298">Schuck et al 2010</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>EMA toxicity may play a role in the neurologic dysfunction observed in <related-object link-type="booklink" source-id="gene" document-id="ee" document-type="chapter">ethylmalonic encephalopathy</related-object>, characterized by psychomotor delays and progressive pyramidal findings resulting from basal ganglia and white matter damage caused by accumulation of large amounts of butyrylcarnitine and EMA [<xref ref-type="bibr" rid="scad.REF.barth.2010.s443">Barth et al 2010</xref>]. However, ethylmalonic encephalopathy is caused by pathogenic variants in <italic toggle="yes">ETHE1,</italic> the gene encoding a mitochondrial protein involved in scavenging reactive oxygen species (ROS); thus, a direct role for EMA in neurotoxicity is not clear.</p>
            </list-item>
            <list-item>
              <p>Butyric acid, which accumulates in SCAD deficiency, can modulate gene expression at high levels as a result of its action as a histone deacetylase [<xref ref-type="bibr" rid="scad.REF.chen.2003.219">Chen et al 2003</xref>]. Its volatile nature may also add to its neurotoxic qualities [<xref ref-type="bibr" rid="scad.REF.chen.2003.219">Chen et al 2003</xref>, <xref ref-type="bibr" rid="scad.REF.pedersen.2008.43">Pedersen et al 2008</xref>, <xref ref-type="bibr" rid="scad.REF.bennett.2010.533">Bennett 2010</xref>].</p>
            </list-item>
            <list-item>
              <p>Most pathogenic variants identified in persons diagnosed with SCAD deficiency, including the Ashkenazi Jewish <italic toggle="yes">ACADS</italic> pathogenic variant <xref ref-type="table" rid="scad.T.selected_acads_variants">c.319C&#x0003e;T</xref>, are missense variants that lead to intramitochondrial aggregation of misfolded protein, suggesting that this protein aggregation itself could be cytotoxic [<xref ref-type="bibr" rid="scad.REF.gregersen.2001.169">Gregersen et al 2001</xref>, <xref ref-type="bibr" rid="scad.REF.pedersen.2008.43">Pedersen et al 2008</xref>, <xref ref-type="bibr" rid="scad.REF.bennett.2010.533">Bennett 2010</xref>]. The majority of diseases associated with misfolded proteins exhibit mitochondrial dysmorphology and evidence of increased oxidative stress in cells. In one in vitro study, astrocytes transfected with <italic toggle="yes">ACADS</italic>
<xref ref-type="table" rid="scad.T.selected_acads_variants">c.319C&#x0003e;T</xref> variant accumulated reactive oxygen species (ROS) and demonstrated mitochondrial dysmorphology consistent with a fission defect that could contribute to cellular apoptosis [<xref ref-type="bibr" rid="scad.REF.schmidt.2010.155">Schmidt et al 2010</xref>]. Thus, it is possible that the effect on SCAD protein misfolding could be modulated by genetic background, which in turn would lead to variable expressivity of disease [<xref ref-type="bibr" rid="scad.REF.tein.2008.179">Tein et al 2008</xref>, <xref ref-type="bibr" rid="scad.REF.schmidt.2010.155">Schmidt et al 2010</xref>].</p>
            </list-item>
          </list>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">ACADS</italic> is approximately 13 kb long; the transcript <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000017.2">NM_000017.2</ext-link> comprises ten exons, and includes 1,238 nucleotides of coding sequence [<xref ref-type="bibr" rid="scad.REF.jethva.2008.195">Jethva et al 2008</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="scad" object-id="scad.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic variants.</bold> At least 70 <italic toggle="yes">ACADS</italic> pathogenic variants, most of which are missense, have been reported.</p>
          <p><bold>Susceptibility variants.</bold> Two missense susceptibility variants have been reported (<xref ref-type="table" rid="scad.T.selected_acads_variants">Table 2</xref>) [<xref ref-type="bibr" rid="scad.REF.van_maldegem.2010c.507">van Maldegem et al 2010c</xref>]. Most individuals who are homozygous for the either variant are asymptomatic, although the presence of the variants is thought to represent a susceptibility state that requires one or more other genetic (e.g., a pathogenic <italic toggle="yes">ACADS</italic> variant in <italic toggle="yes">trans</italic>) or environmental factors to be present for disease to development [<xref ref-type="bibr" rid="scad.REF.gregersen.2001.169">Gregersen et al 2001</xref>, <xref ref-type="bibr" rid="scad.REF.van_maldegem.2010c.507">van Maldegem et al 2010c</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>c.511C&#x0003e;T in exon 5</p>
            </list-item>
            <list-item>
              <p>c. 625G&#x0003e;A in exon 6</p>
            </list-item>
          </list>
          <p>Both variants are relatively common in the general population.</p>
          <list list-type="bullet">
            <list-item>
              <p>In a study of 694 newborns in the United States, approximately 6% were c.625G&#x0003e;A homozygous, 0.3% were c.511C&#x0003e;T homozygous, and 0.9% were compound heterozygous (one allele with each variation) [<xref ref-type="bibr" rid="scad.REF.van_maldegem.2010c.507">van Maldegem et al 2010c</xref>]. This provides an allele frequency of 0.22 for the c.625G&#x0003e;A variant and 0.03 for the c.511C&#x0003e;T variant.</p>
            </list-item>
            <list-item>
              <p>In the US, 7% of the population is estimated to be either homozygous for one of the susceptibility variants or compound heterozygous [<xref ref-type="bibr" rid="scad.REF.lindner.2010.521">Lindner et al 2010</xref>]. Individuals homozygous for one of the variants have an increased incidence of excretion of EMA [<xref ref-type="bibr" rid="scad.REF.bennett.2010.533">Bennett 2010</xref>].</p>
            </list-item>
            <list-item>
              <p>In one European study, 14% of controls were homozygous for one of the variants as compared to 69% of 133 subjects with increased urinary EMA excretion.</p>
            </list-item>
          </list>
          <table-wrap id="scad.T.selected_acads_variants" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Selected <italic toggle="yes">ACADS</italic> Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_scad.T.selected_acads_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classificiation</th>
                  <th id="hd_h_scad.T.selected_acads_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_scad.T.selected_acads_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_scad.T.selected_acads_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_scad.T.selected_acads_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Pathogenic</bold>
                  </td>
                  <td headers="hd_h_scad.T.selected_acads_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.319C&#x0003e;T<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=61732144">rs61732144</ext-link></td>
                  <td headers="hd_h_scad.T.selected_acads_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg107Cys&#x000a0;<sup>2</sup><break/>(Arg83Cys)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_scad.T.selected_acads_variants_1_1_1_4" rowspan="3" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000017.2">NM_000017.2</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000008.1">NP_000008.1</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_scad.T.selected_acads_variants_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1"><bold>Susceptibility variants</bold><break/>(i.e., common variants with uncertain pathogenicity)</td>
                  <td headers="hd_h_scad.T.selected_acads_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.511C&#x0003e;T<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1800556">rs1800556</ext-link></td>
                  <td headers="hd_h_scad.T.selected_acads_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg171Trp&#x000a0;<sup>2</sup><break/>(Arg147Trp)&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_scad.T.selected_acads_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.625G&#x0003e;A<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1799958">rs1799958</ext-link></td>
                  <td headers="hd_h_scad.T.selected_acads_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly209Ser&#x000a0;<sup>2</sup><break/>(Gly185Ser)&#x000a0;<sup>3</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="scad.TF.2.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
              <fn id="scad.TF.2.2">
                <label>2. </label>
                <p>Residue in the precursor peptide</p>
              </fn>
              <fn id="scad.TF.2.3">
                <label>3. </label>
                <p>Residue in the mature enzyme, after cleavage of the 24 N-terminal amino acids of the transit peptide that directs the protein to the mitochondria</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> Short chain-specific acyl-CoA dehydrogenase, mitochondrial (SCAD) like all of the acyl-CoA dehydrogenases (ACAD), is a flavoprotein synthesized in the cytosol as a precursor protein that is transported to and further processed to a mature form in mitochondria including proteolytic cleavage of a mitochondrial targeting (transit) peptide at the amino terminus [<xref ref-type="bibr" rid="scad.REF.battaile.2002.12200">Battaile et al 2002</xref>].</p>
          <p>Study of the crystal structure of recombinant rat SCAD has revealed a homotetramer arranged as a dimer of dimers that is highly conserved with the other ACAD structures: a glutamic acid residue located at amino acid position 368 of the mature rat SCAD protein (homologous to position 376 in MCAD acts as the catalytic base to initiate the catalytic reaction [<xref ref-type="bibr" rid="scad.REF.battaile.2002.12200">Battaile et al 2002</xref>]. In vitro studies show that mutation of this residue in the rat SCAD enzyme to a Gln or Ala inactivates the enzyme. Each enzyme also has amino acid residues specific to its particular function. In vitro studies in rat SCAD also show that amino acid residues Gln254 and Thr364 appear to shorten the substrate binding pocket and contribute to its substrate specificity [<xref ref-type="bibr" rid="scad.REF.kim.1993">Kim et al 1993</xref>].</p>
          <p><bold>Abnormal gene product.</bold> Nearly all individuals identified with short-chain acyl-CoA dehydrogenase (SCAD) deficiency described to date have pathogenic missense variants that lead to protein misfolding, which may provide insight into possible pathologic effects of SCAD [<xref ref-type="bibr" rid="scad.REF.schmidt.2010.155">Schmidt et al 2010</xref>]. The loss of SCAD enzymatic activity clearly leads to the accumulation of abnormal organic acids; the true risk of this loss of function may be acute metabolic acidosis with physiologic stress [<xref ref-type="bibr" rid="scad.REF.schuck.2010.298">Schuck et al 2010</xref>]. Aggregation of abnormally folded SCAD protein in patient cells is distinct and may lead to otherwise unexpected cellular toxicity [<xref ref-type="bibr" rid="scad.REF.schuck.2010.298">Schuck et al 2010</xref>]. Moreover, SCAD misfolding is aggravated by environmental factors that may vary person to person, and interact with currently uncharacterized factors to cause disease in some individuals [<xref ref-type="bibr" rid="scad.REF.gregersen.2001.169">Gregersen et al 2001</xref>, <xref ref-type="bibr" rid="scad.REF.pedersen.2008.43">Pedersen et al 2008</xref>, <xref ref-type="bibr" rid="scad.REF.bennett.2010.533">Bennett 2010</xref>].</p>
        </sec>
      </sec>
      <sec id="scad.References">
        <title>References</title>
        <sec id="scad.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="scad.Literature_Cited.reflist0">
            <ref id="scad.REF.amendt.1987.1303">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Amendt</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greene</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sweetman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cloherty</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shih</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teel</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rhead</surname>
                    <given-names>WJ</given-names>
                  </name>
                </person-group>
                <year>1987</year>
                <article-title>Short-chain acyl-coenzyme A dehydrogenase deficiency. Clinical and biochemical studies in two patients.</article-title>
                <source>J Clin Invest.</source>
                <volume>79</volume>
                <fpage>1303</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">3571488</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.barschak.2006.11">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barschak</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreira Gda</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andr&#x000e9;</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuck</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viegas</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tonin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dutra Filho</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wyse</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wannmacher</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vargas</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wajner</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Inhibition of the electron transport chain and creatine kinase activity by ethylmalonic acid in human skeletal muscle.</article-title>
                <source>Metab Brain Dis.</source>
                <volume>21</volume>
                <fpage>11</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16773466</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.barth.2010.s443">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ottolenghi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hubert</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chr&#x000e9;tien</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serre</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gobin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vassault</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sefiani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricquier</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boddaert</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brivet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Keyzer</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rabier</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valayannopoulos</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P.</given-names>
                  </name>
                </person-group>
                <article-title>Multiple sources of metabolic disturbance in ETHE1-related ethylmalonic encephalopathy.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2010</year>
                <month>Dec</month>
                <volume>33</volume>
                <supplement>Suppl 3</supplement>
                <fpage>S443</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">20978941</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.battaile.2002.12200">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Battaile</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Molin-Case</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschke</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vockley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>JJ</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Crystal structure of rat short chain acyl-CoA dehydrogenase complexed with acetoacetyl-CoA: comparison with other acyl-CoA dehydrogenases.</article-title>
                <source>J Biol Chem.</source>
                <volume>277</volume>
                <fpage>12200</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11812788</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.bennett.2010.533">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Pathophysiology of fatty acid oxidation disorders.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>33</volume>
                <fpage>533</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20824345</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.bok.2003.1152">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bok</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vreken</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corydon</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Short-chain Acyl-CoA dehydrogenase deficiency: studies in a large family adding to the complexity of the disorder.</article-title>
                <source>Pediatrics.</source>
                <volume>112</volume>
                <fpage>1152</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">14595061</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.chen.2003.219">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faller</surname>
                    <given-names>DV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spanjaard</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics?</article-title>
                <source>Curr Cancer Drug Targets.</source>
                <volume>3</volume>
                <fpage>219</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">12769690</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.corydon.2001.18">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Corydon</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vockley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinaldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rhead</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kjeldsen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winter</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riggs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Babovic-Vuksanovic</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeitink</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jong</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewell</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roe</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dasouki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Role of common gene variations in the molecular pathogenesis of short-chain acyl-CoA dehydrogenase deficiency.</article-title>
                <source>Pediatr Res.</source>
                <volume>49</volume>
                <fpage>18</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">11134486</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.gallant.2012.55">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gallant</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leydiker</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feuchtbaum</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorey</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puckett</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deignan</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neidich</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dorrani</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barshop</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cederbaum</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdenur</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Biochemical, molecular, and clinical characteristics of children with short-chain acyl-CoA dehydrogenase deficiency detected by newborn screening in California.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>106</volume>
                <fpage>55</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">22424739</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.gregersen.2001.169">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andresen</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corydon</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corydon</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olsen</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolund</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bross</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship.</article-title>
                <source>Hum Mutat.</source>
                <volume>18</volume>
                <fpage>169</fpage>
                <lpage>89</lpage>
                <pub-id pub-id-type="pmid">11524729</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.jethva.2008.195">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jethva</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vockley</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Short-chain acyl-coenzyme A dehydrogenase deficiency.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>95</volume>
                <fpage>195</fpage>
                <lpage>200</lpage>
                <pub-id pub-id-type="pmid">18977676</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.kim.1993">
              <mixed-citation publication-type="book">Kim JJP, Wang M, Djordjevic S, Paschke R, Bennett DW. Three-dimensional structures of acyl-CoA dehydrogenases: structural basis of substrate specificity. In: Yagi K, ed. <italic toggle="yes">Flavins and Flavoproteins</italic>. New York, NY: Walter de Gruyter; 1993:273-82</mixed-citation>
            </ref>
            <ref id="scad.REF.lindner.2010.521">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lindner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>33</volume>
                <fpage>521</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20373143</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.matern.2001.585">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hart</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murtha</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vockley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millington</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Treem</surname>
                    <given-names>WR</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Acute fatty liver of pregnancy associated with short-chain acyl-coenzyme A dehydrogenase deficiency.</article-title>
                <source>J Pediatr.</source>
                <volume>138</volume>
                <fpage>585</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11295727</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.pedersen.2008.43">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pedersen</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000f8;lvraa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000f8;lvraa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stenbroen</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kjeldsen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ensenauer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tein</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinaldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vianey-Saban</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehnert</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christensen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corydon</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andresen</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolund</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vockley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bross</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level.</article-title>
                <source>Hum Genet.</source>
                <volume>124</volume>
                <fpage>43</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">18523805</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.schmidt.2010.155">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corydon</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pedersen</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bross</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Misfolding of short-chain acyl-CoA dehydrogenase leads to mitochondrial fission and oxidative stress.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>100</volume>
                <fpage>155</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">20371198</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.schuck.2010.298">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schuck</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Busanello</surname>
                    <given-names>EN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moura</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tonin</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grings</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ritter</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vargas</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>da Costa Ferreira</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wajner</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Promotion of lipid and protein oxidative damage in rat brain by ethylmalonic acid.</article-title>
                <source>Neurochem Res.</source>
                <volume>35</volume>
                <fpage>298</fpage>
                <lpage>305</lpage>
                <pub-id pub-id-type="pmid">19757035</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.tein.2008.179">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tein</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben-Zeev</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korman</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lossos</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lev</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lerman-Sagie</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leshinsky-Silver</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vockley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry</surname>
                    <given-names>GT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamhonwah</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roe</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Short-chain acyl-CoA dehydrogenase gene mutation (c.319C&#x0003e;T) presents with clinical heterogeneity and is candidate founder mutation in individuals of Ashkenazi Jewish origin.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>93</volume>
                <fpage>179</fpage>
                <lpage>89</lpage>
                <pub-id pub-id-type="pmid">18054510</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.tiranti.2004.239">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Adamo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briem</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrari</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mineri</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamantea</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balestri</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Silva</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vollmer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinaldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hahn</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leonard</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dionisi-Vici</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garavaglia</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasparini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>74</volume>
                <fpage>239</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">14732903</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.van_maldegem.2006.943">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Maldegem</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niezen-Koning</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hogeveen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ijlst</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase deficiency</article-title>
                <source>Jama</source>
                <volume>296</volume>
                <fpage>943</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">16926354</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.van_maldegem.2010a.121">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Maldegem</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Koning</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                </person-group>
                <year>2010a</year>
                <article-title>Fasting and fat-loading tests provide pathophysiological insight into short-chain acyl-coenzyme a dehydrogenase deficiency.</article-title>
                <source>J Pediatr.</source>
                <volume>156</volume>
                <fpage>121</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19800078</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.van_maldegem.2010b.304">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Maldegem</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                </person-group>
                <year>2010b</year>
                <article-title>Flavin adenine dinucleotide status and the effects of high-dose riboflavin treatment in short-chain acyl-CoA dehydrogenase deficiency.</article-title>
                <source>Pediatr Res.</source>
                <volume>67</volume>
                <fpage>304</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19952864</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.van_maldegem.2010c.507">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Maldegem</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                </person-group>
                <year>2010c</year>
                <article-title>Clinical aspects of short-chain acyl-CoA dehydrogenase deficiency</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>33</volume>
                <fpage>507</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">20429031</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.waisbren.2008.39">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Waisbren</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>HL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noble</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasley</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsden</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Short-chain acyl-CoA dehydrogenase (SCAD) deficiency: an examination of the medical and neurodevelopmental characteristics of 14 cases identified through newborn screening or clinical symptoms.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>95</volume>
                <fpage>39</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">18676165</pub-id>
              </element-citation>
            </ref>
            <ref id="scad.REF.young.2003.103">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevens</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koeberl</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millington</surname>
                    <given-names>DS</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>A comparison of in vitro acylcarnitine profiling methods for the diagnosis of classical and variant short chain acyl-CoA dehydrogenase deficiency.</article-title>
                <source>Clin Chim Acta.</source>
                <volume>337</volume>
                <fpage>103</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">14568186</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="scad.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="scad.Author_Notes">
          <title>Author Notes</title>
          <p>The American College of Medical Genetics has published online an algorithm delineating the appropriate response to an elevated C4 on newborn screening (<named-content content-type="highlight-1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.acmg.net/StaticContent/ACT/C4.pdf">ACMG-ACT Sheet</ext-link></named-content> and <named-content content-type="highlight-1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.acmg.net/StaticContent/ACT/Algorithms/Visio-C4.pdf">ACMG Algorithm</ext-link></named-content> [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.acmg.net/">www.acmg.net</ext-link>]).</p>
        </sec>
        <sec id="scad.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>7 August 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>22 September 2011 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>21 March 2011 (lw) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
